Search results
Showing 4996 to 5010 of 5124 results for technology
Chemotherapy-free treatment option to be offered to patients with England's most common leukaemia
Acalabrutinib, taken as a twice daily tablet, is recommended as an option for adults with untreated chronic lymphocytic leukaemia.
Paper looks at how histology-independent cancer drugs might be appraised
Dr Roberts, who is a qualified doctor, has 20 years’ experience in clinical and management posts in healthcare both in the private and public sector.
Dr Sam Roberts welcomes Dr Michael Borowitz as new NICE non-executive director
New NICE non-executive director appointment approved by the Secretary of State for Health and Social Care
NICE has approved the use of nalmefene to help people who are dependent on alcohol to cut down on the amount they drink.
Eight digital enabled therapies to treat depression and anxiety disorders in adults have been conditionally recommended by NICE in draft guidance issued today (Wednesday 1 March 2023).
Leading experts have dismissed claims that the formula used by NICE to recommend which drugs are funded on the NHS is 'flawed' and say that it is still the best available method for assessing drugs.
Would you like to find high quality evidenced-based information more quickly and easily? Are you looking for a one-stop resource that collates information from all the best sources ? such as Royal Colleges and the BNF?
Children with a rare, fatal, genetic disorder will be able to benefit from a new one-off treatment under new NICE guidance.
Patients with relapsing remitting multiple sclerosis can now be offered a pill that helps reduce the number of relapses, says NICE.
Breast cancer patients to have further NICE-approved drug combination option on Cancer Drugs Fund
Another potentially life-extending drug combination for some people with advanced breast cancer will now be available on the Cancer Drugs Fund (CDF) following its approval by NICE in final guidance published today (15 January 2020).
Cancer patients to benefit from new histology independent treatment
Entrectinib (Rozlytrek, Roche), a revolutionary treatment for a range of cancers, is the second histology independent drug to be recommended by NICE for use on the Cancer Drugs Fund (CDF).
Broader types of data to be used in development of NICE guidance
An expanded evidence base could allow NICE to address evidence gaps and enhance reviews of the impact of our guidance
Call for abstracts for HTAi 2021 Annual Meeting in Manchester
Health Technology Assessment International (HTAi) has released the plenary themes for the HTAi 2021 Annual Meeting and opened their call for abstract submissions
When a GP suspects a child or young person has diabetes, they should immediately be sent to hospital and seen the same day by a specialist, a new NICE quality standard says.